At the time of writing, Centessa Pharmaceuticals plc ADR [CNTA] stock is trading at $22.92, up 3.24%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CNTA shares have gain 4.09% over the last week, with a monthly amount drifted -8.25%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Stephens started tracking the stock with Overweight rating on October 28, 2025, and set its price target to $35. On September 03, 2025, Wells Fargo initiated with a Overweight rating and assigned a price target of $31 on the stock. Truist initiated its recommendation with a Buy and recommended $30 as its price target on July 21, 2025. Needham started tracking with a Buy rating for this stock on May 28, 2025, and assigned it a price target of $35. In a note dated May 08, 2025, Chardan Capital Markets initiated an Buy rating and provided a target price of $30 on this stock.
For the past year, the stock price of Centessa Pharmaceuticals plc ADR fluctuated between $9.60 and $30.58. Currently, Wall Street analysts expect the stock to reach $35.8 within the next 12 months. Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] shares were valued at $22.92 at the most recent close of the market. An investor can expect a potential return of 56.2% based on the average CNTA price forecast.
Analyzing the CNTA fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -14.25%, Pretax Profit Margin comes in at -15.95%, and Net Profit Margin reading is -16.18%. To continue investigating profitability, this company’s Return on Assets is posted at -0.54, Equity is -0.68 and Total Capital is -0.51. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.39.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Centessa Pharmaceuticals plc ADR [NASDAQ:CNTA] has a current ratio of 10.57. In addition, the Quick Ratio stands at 10.57 and the Cash Ratio stands at 1.74. Considering the valuation of this stock, the price to sales ratio is 204.58, the price to book ratio is 10.22.
Transactions by insiders
Recent insider trading involved Saurabh Saha, Previous Officer, that happened on Jan 02 ’26 when 2.5 million shares were purchased. President, Orexin Program, Accardi Mario Alberto completed a deal on Dec 09 ’25 to sell 10000.0 shares. Meanwhile, Officer Accardi Mario Alberto bought 10000.0 shares on Dec 09 ’25.
